Plain-English translation of NCT07166757 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing XS411, a treatment made from specially grown stem cells that produce dopamine, a brain chemical that is low in people with Parkinson's disease. Researchers will inject these cells directly into the brain to see if they can help reduce movement problems and improve quality of life. The study has two phases: first, a small safety phase to find the right dose, and then a larger phase to see how well the treatment works compared to a sham procedure.
Current Parkinson's medications often become less effective over time, and people develop unpredictable movement problems that are hard to control. This medication is being tested as a potential way to replace damaged brain cells and provide longer-lasting improvement in symptoms.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will either receive a surgical injection of the stem cell treatment into your brain under anesthesia (combined with medication to prevent rejection) or a sham procedure, depending on which group you're assigned to. You will need to commit to at least 24 months of follow-up visits and testing to monitor your symptoms, safety, and any side effects. During this time, you cannot have other elective brain surgery and must avoid enrolling in other clinical studies.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China